Advancements in Liposomal Drug Delivery and Nanocarrier Systems for Targeted Therapeutics

Liposomal delivery of drugs and nanocarrier platforms are now revolutionized platforms for today's therapeutics, including better drug solubility, sustained circulation, and site-directed targeting. History and overview of liposomal drug delivery is addressed here, its formation, its types, and how it becomes functionalized. Advances in stealth technology and commercial FDA-approved formulations such as Doxil®, illustrate their place in cancer chemotherapy as well as general therapeutics. Comparison with micellar nanocarriers, solid lipid nanoparticles (SLNs), polymeric nanoparticles, and hybrid vesicular systems provides a scenario of the pros and cons of liposomes.Despite their advantages, liposomal systems are faced with targeting specificity, large-scale manufacture, and stability. The paper also identifies some of the up-and-coming trends in nanomedicine such as stimuli-responsive liposomes and hybrid carrier systems that aim at enhanced drug encapsulation, release kinetics, and therapeutic efficacy. All these have promising prospects for the future of liposomal technology in next-generation therapeutics to unlock improved drug delivery strategies with higher efficacy and fewer side effects.